Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight: Amgen
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes
2022
2021
2020
Relapsed/Refractory Follicular Lymphoma
PET/CT Imaging in Prostate Cancer Patients
NTRK
Gene Fusions
Ovarian Cancer Series
PET/CT Imaging in Prostate Cancer Patients
Overview of the Molecular Characteristics of PYLARIFY
By
Steven Rowe, MD, PhD
Interview with the Innovators
Dr Steven Rowe details the molecular characteristics of PYLARIFY® (piflufolastat F 18) and the OSPREY and CONDOR pivotal trials, which led to the FDA approval of PYLARIFY®.
Read More ›
Practical Applications and Clinical Utility of PYLARIFY® (piflufolastat F 18) Injection: An ¹⁸F-PSMA PET/CT Imaging Agent for Prostate Cancer
Interview with the Innovators
,
Prostate Cancer
A series of interviews was recently conducted with a panel of experts on prostate cancer imaging modalities that included Steven Rowe, MD, PhD, Associate Professor of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, and Neal D. Shore, MD, FACS, CMO, Surgical Oncology/Urology Genesis Care, US; Director, CPI, Carolina Urologic Research Center, Myrtle Beach, SC.
Read More ›
PET/CT Imaging in Prostate Cancer Patients
The Importance of Accurate Staging in Prostate Cancer
By
Neal Shore, MD, FACS
Interview with the Innovators
Dr Neal Shore emphasizes the importance of accurate staging of prostate cancer and how PYLARIFY® (piflufolastat F 18) can improve treatment decision-making in patients with prostate cancer.
Read More ›
PET/CT Imaging in Prostate Cancer Patients
Use of PYLARIFY® in Specific Patient Groups
By
Neal Shore, MD, FACS
Interview with the Innovators
Dr Neal Shore highlights example patient populations that may benefit from improved staging through the use of PYLARIFY® (piflufolastat F 18), a prostate-specific membrane antigen (PSMA)-targeted PET/CT agent.
Read More ›
PET/CT Imaging in Prostate Cancer Patients
PSMA PET Imaging in Patients with Oligometastatic Prostate Cancer
Interview with the Innovators
Dr Neal Shore discusses the importance of PSMA PET imaging across a range of PSA values and how PYLARIFY® (piflufolastat F 18) will affect imaging of patients with oligometastatic prostate cancer.
Read More ›
PET/CT Imaging in Prostate Cancer Patients
PYLARIFY and Next-Generation Imaging
By
Neal Shore, MD, FACS
Interview with the Innovators
Dr Neal Shore elaborates on the ability of PYLARIFY® (piflufolastat F 18) to detect metastases and the practical aspects of next-generation imaging.
Read More ›
PET/CT Imaging in Prostate Cancer Patients
PSMA-Targeted Imaging for Prostate Cancer Treatment
By
Neal Shore, MD, FACS
Interview with the Innovators
Dr Neal Shore discusses the rationale of prostate-specific membrane antigen (PSMA) PET/CT to guide prostate cancer treatment.
Read More ›
PET/CT Imaging in Prostate Cancer Patients
Overview of Current Imaging Modalities in Prostate Cancer
By
Neal Shore, MD, FACS
Interview with the Innovators
Dr Neal Shore introduces the current global landscape of various imaging modalities for prostate cancer, including a new prostate-specific membrane antigen (PSMA)-targeted PET/CT agent, PYLARIFY
®
(piflufolastat F 18).
Read More ›
End-of-Life Care: Moving Beyond Practical Needs of Patients to Emotional Needs of People
By
Kristin Siyahian
Interview with the Innovators
An Interview with Kelly Grosklags, LICSW, BCD, FAAGC
Read More ›
NTRK Gene Fusions
Making a Difference with Early Identification and Treatment of Patients with NTRK Gene Fusions
By
Ezra Cohen, MD, FRCPSC, FASCO
;
Mary Jo Fidler, MD
;
Arturo Loaiza-Bonilla, MD, MSEd, FACP
Interview with the Innovators
Dr Ezra Cohen of UC San Diego, La Jolla, CA; Dr Mary Fidler of Rush University Medical Center, Chicago, IL; and Dr Arturo Loaiza-Bonilla of the Comprehensive Care and Research Center, Philadelphia, PA, explain the benefits of testing for
TRK
fusion–positive tumors early for improved clinical outcomes.
Read More ›
Page 2 of 5
1
2
3
4
5
View the Latest Issue of OPM
Read Issue
Top Trending Articles
1.
Molecular Characteristics Increasingly Define Adult Gliomas
By
William King
2.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
By
William King
3.
Optimal Systemic Therapy for Renal Cell Carcinoma Is Still Evolving
By
William King
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight: Amgen
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes